Gene therapy for hemophilia B

Hemophilia B patients do not produce sufficient amounts of coagulation factor IX and consequently have reduced clotting activity and suffer from acute bleeding episodes. Since hemophilia B results from genetic defects in the gene for factor IX, it is possible to treat the disorder using gene therapy to either correct or replace the defective gene so that active factor IX can be continuously produced in the patient. Conventional gene therapy …